Equities analysts predict that Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) will post $70,000.00 in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Bellicum Pharmaceuticals’ earnings, with estimates ranging from $30,000.00 to $100,000.00. Bellicum Pharmaceuticals posted sales of $110,000.00 during the same quarter last year, which suggests a negative year-over-year growth rate of 36.4%. The firm is scheduled to announce its next earnings results on Wednesday, November 8th.

On average, analysts expect that Bellicum Pharmaceuticals will report full-year sales of $70,000.00 for the current year, with estimates ranging from $100,000.00 to $300,000.00. For the next year, analysts forecast that the firm will report sales of $810,000.00 per share, with estimates ranging from $120,000.00 to $2.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same period in the prior year, the company earned ($0.61) EPS.

A number of analysts have issued reports on BLCM shares. Wells Fargo & Company reiterated an “outperform” rating and issued a $31.00 price target on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Raymond James Financial, Inc. reiterated a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $35.00 price target on shares of Bellicum Pharmaceuticals in a research report on Monday, June 26th. BidaskClub upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $16.00 price target (down from $18.00) on shares of Bellicum Pharmaceuticals in a research report on Thursday, August 10th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. Bellicum Pharmaceuticals has a consensus rating of “Hold” and an average target price of $26.20.

COPYRIGHT VIOLATION NOTICE: “Brokerages Expect Bellicum Pharmaceuticals, Inc. (BLCM) Will Post Quarterly Sales of $70,000.00” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/09/14/brokerages-expect-bellicum-pharmaceuticals-inc-blcm-will-post-quarterly-sales-of-70000-00.html.

Shares of Bellicum Pharmaceuticals (NASDAQ BLCM) opened at 10.26 on Thursday. The stock’s 50 day moving average price is $9.58 and its 200-day moving average price is $11.74. Bellicum Pharmaceuticals has a 52-week low of $7.41 and a 52-week high of $23.11. The company’s market capitalization is $340.90 million.

In related news, VP Ken Moseley sold 13,823 shares of Bellicum Pharmaceuticals stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $12.26, for a total transaction of $169,469.98. Following the completion of the sale, the vice president now owns 14,314 shares of the company’s stock, valued at $175,489.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider David M. Spencer sold 10,000 shares of Bellicum Pharmaceuticals stock in a transaction on Monday, July 10th. The shares were sold at an average price of $11.54, for a total value of $115,400.00. The disclosure for this sale can be found here. Insiders have sold 24,260 shares of company stock valued at $290,048 in the last three months. 23.30% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its stake in Bellicum Pharmaceuticals by 10.2% during the second quarter. JPMorgan Chase & Co. now owns 2,466,752 shares of the biopharmaceutical company’s stock valued at $28,811,000 after buying an additional 227,668 shares during the period. Vanguard Group Inc. boosted its stake in Bellicum Pharmaceuticals by 13.6% during the second quarter. Vanguard Group Inc. now owns 1,206,436 shares of the biopharmaceutical company’s stock valued at $14,092,000 after buying an additional 144,854 shares during the period. Foresite Capital Management III LLC bought a new stake in Bellicum Pharmaceuticals during the first quarter valued at $11,328,000. Kennedy Capital Management Inc. boosted its stake in Bellicum Pharmaceuticals by 32.1% during the first quarter. Kennedy Capital Management Inc. now owns 632,065 shares of the biopharmaceutical company’s stock valued at $7,800,000 after buying an additional 153,600 shares during the period. Finally, State Street Corp boosted its stake in Bellicum Pharmaceuticals by 16.6% during the second quarter. State Street Corp now owns 416,966 shares of the biopharmaceutical company’s stock valued at $4,872,000 after buying an additional 59,321 shares during the period. 55.73% of the stock is owned by institutional investors.

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.